5-Lipoxygenase: its involvement in gastrointestinal malignancies

Chronic inflammation is increasingly known as one of the most critical etiological factors in gastrointestinal (GI) cancers (Lee et al., 2016; Wang and Cho, 2015). Overexpression of 5-lipoxygenase (5-LOX), 5-LOX-activating protein (FLAP), as well as other leukotriene (LT) biosynthetic enzymes have been reported in many malignant cells of the GI tract including the colon, rectum, esophagus, and pancreas (Chen et al., 2004; Li et al., 2005; Melstrom et al., 2008; Wasilewicz et al., 2010). There are several pieces of evidence suggesting that 5-LOX triggers the progression and initiation of GI malignancies (Moore and Pidgeon, 2017; Ringleb et al., 2018).

Source: Critical Reviews in Oncology Hematology - May 17, 2018 Category: Cancer & Oncology Authors: Neha Merchant, Lakkakula Venkata Kameswara Subrahmanya Bhaskar, Saimila Momin, Peela Sujatha, Aramati B.M. Reddy, Ganji Purnachandra Nagaraju Source Type: research